Clinical Trials Logo

Intestinal Neoplasms clinical trials

View clinical trials related to Intestinal Neoplasms.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05848843 Withdrawn - Lung Cancer Clinical Trials

A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

Start date: April 25, 2023
Phase: Phase 1
Study type: Interventional

To find a recommended dose of the combination of adagrasib and durvalumab that can be given to patients with cancers that have a KRAS G12C mutation.

NCT ID: NCT05471401 Withdrawn - Lung Cancer Clinical Trials

GI Organ Tracking Via Balloon Applicators

Start date: April 25, 2023
Phase: N/A
Study type: Interventional

The hypothesis of this study is that an occlusion balloon catheter placed in the stomach via an oral or nasogastric route will be safe and permit tracking of the stomach during radiation therapy.

NCT ID: NCT04811833 Withdrawn - Clinical trials for Gastrointestinal Stromal Tumors

Gastrointestinal Anastomosis Using MonoPlus® Suture

GASTROMO
Start date: July 2022
Phase:
Study type: Observational

The primary aim of this study is to collect clinical data on the performance of MonoPlus® suture applied in routine clinical practice. Diverse parameters are to be used to assess the safety and efficacy of MonoPlus® suture for gastrointestinal anastomosis construction. This study has been designed to implement an action within the framework of a proactive Post Market Clinical Follow up (PMCF) activity.

NCT ID: NCT00621036 Withdrawn - Lymphoma Clinical Trials

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

Start date: October 19, 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines made from a person's cancer proteins may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving vaccine therapy together with GM-CSF may make a stronger immune response and kill more cancer cells. PURPOSE: This phase II trial is studying the side effects and how well giving vaccine therapy together with GM-CSF works in treating patients with CNS lymphoma.